Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
LA1-M52H3 | Mouse | Mouse LAIR1 / CD305 Protein, His Tag (MALS verified) |
|
||
LA1-H82F5 | Human | Biotinylated Human LAIR1 / CD305 Protein, Fc,Avitag™ (MALS verified) |
|
||
LA1-H5253 | Human | Human LAIR-1 Protein, Mouse IgG2a Fc Tag |
|
||
LA1-M5254 | Mouse | Mouse LAIR1 / CD305 Protein, Mouse IgG2a Fc Tag, low endotoxin |
|
||
LA1-C52A3 | Rhesus macaque | Rhesus macaque LAIR-1 / CD305 Protein, Mouse IgG2a Fc Tag |
|
||
LA1-H82E3 | Human | Biotinylated Human LAIR1 / CD305 Protein, His,Avitag™ |
|
||
LA1-H5252 | Human | Human LAIR1 / CD305 Protein, Fc Tag (MALS verified) |
|
||
CD5-H52H1 | Human | Human LAIR1 / CD305 Protein, His Tag |
|
Immobilized Native Human Collagen I protein at 10 μg/mL (100 μL/well) can bind Biotinylated Human LAIR-1, Fc,Avitag (Cat. No. LA1-H82F5) with a linear range of 0.01-0.625 μg/mL (QC tested).
The purity of Mouse LAIR1 Protein, His Tag (Cat. No. LA1-M52H3) is more than 90% and the molecular weight of this protein is around 20-28 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
NC-410 | NC-410 | Phase 2 Clinical | Nextcure Inc | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Colorectal Neoplasms | Details |
NGM-438 | NGM-438 | Phase 1 Clinical | Merck & Co Inc, Ngm Biopharmaceuticals Inc | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Mesothelioma; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma | Details |
NC-410 | NC-410 | Phase 2 Clinical | Nextcure Inc | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Colorectal Neoplasms | Details |
NGM-438 | NGM-438 | Phase 1 Clinical | Merck & Co Inc, Ngm Biopharmaceuticals Inc | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Mesothelioma; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma | Details |
NC-410 | NC-410 | Phase 2 Clinical | Nextcure Inc | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Colorectal Neoplasms | Details |
NGM-438 | NGM-438 | Phase 1 Clinical | Merck & Co Inc, Ngm Biopharmaceuticals Inc | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Mesothelioma; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma | Details |
NC-410 | NC-410 | Phase 2 Clinical | Nextcure Inc | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Colorectal Neoplasms | Details |
NGM-438 | NGM-438 | Phase 1 Clinical | Merck & Co Inc, Ngm Biopharmaceuticals Inc | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Mesothelioma; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma | Details |
This web search service is supported by Google Inc.